| Rezurock (belumosudil) / Romeck Pharma, Sanofi |
NCT06616415: A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies |
|
|
| Recruiting | 4 | 6 | RoW | Belumosudil, SAR445761/ KD025, Rezurock | Sanofi | Chronic Graft Versus Host Disease | 05/26 | 05/26 | | |
ROCKnrol-1, NCT06143891: A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. |
|
|
| Recruiting | 3 | 260 | Europe, Canada, US, RoW | Belumosudil, SAR445761/ KD025, REZUROCK, Placebo, Prednisone, Prednisolone | Sanofi | Chronic Graft Versus Host Disease | 09/28 | 09/28 | | |
ROCKaspire, NCT06082037: A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction |
|
|
| Recruiting | 3 | 180 | Europe, Canada, US, RoW | Belumosudil, REZUROCK, Azithromycin, Placebo | Sanofi | Lung Transplant Rejection | 09/26 | 06/28 | | |
NCT04930562: Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD) |
|
|
| Completed | 2 | 30 | RoW | BN101, belumosudil, KD025 | BioNova Pharmaceuticals (Shanghai) LTD. | GVHD, Chronic | 06/22 | 12/22 | | |
NCT03919799: KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis |
|
|
| Terminated | 2 | 36 | US | Belumosudil (KD025), Placebo | Kadmon, a Sanofi Company | System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis | 08/22 | 02/23 | | |
|
2024-000203-67: Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy |
|
|
| Not yet recruiting | 2 | 270 | US | Sar445761, Sar445761, Film-coated tablet | Kadmon Corporation, LLC, Kadmon Corporation, LLC | Chronic graft-versus-host-disease, Chronic graft-versus-host-disease, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05305989: Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 |
|
|
| Completed | 2 | 23 | US | Belumosudil 200 mg QD, REZUROCK, Belumosudil 200 mg BID, Belumosudil 400 mg QD | Kadmon, a Sanofi Company | Chronic Graft-versus-host-disease | 06/24 | 06/24 | | |
NCT05922761: BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) |
|
|
| Recruiting | 2 | 45 | US | Belumosudil, Rezurock, KD025, 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, C26H24N6O2, Fluticasone, Fluticasone Propionate, Azithromycin, Zithromax, Prednisone, Montelukast, Singulair | Dana-Farber Cancer Institute, Sanofi, National Heart, Lung, and Blood Institute (NHLBI) | Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease | 06/26 | 12/26 | | |
NCT06751602: Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation |
|
|
| Not yet recruiting | 2 | 40 | US | Belumosudil 200 mg QD, Rezurock, Belumosudil, Placebo | The Methodist Hospital Research Institute | Rejection Chronic Renal, Interstitial Fibrosis/tubular Atrophy of Transplanted Kidneys | 09/27 | 03/28 | | |
CLAD, NCT06476132: Belumosudil to Block Chronic Lung Allograft Dysfunction () in High Risk Lung Transplant Recipients |
|
|
| Not yet recruiting | 2 | 234 | Canada, US | Belumosudil, Placebo for Belumosudil | National Institute of Allergy and Infectious Diseases (NIAID) | Lung Transplant | 05/27 | 06/27 | | |
NCT05567406: Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy |
|
|
| Recruiting | 2 | 36 | US | Belumosudil, KD025, SAR445761, Rezurock | Kadmon, a Sanofi Company | Chronic Graft Versus Host Disease | 08/25 | 08/25 | | |
ROCKstar, NCT03640481: Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy |
|
|
| Terminated | 2 | 159 | US | Belumosudil (KD025), REZUROCK | Kadmon, a Sanofi Company | Chronic Graft-versus-host-disease | 12/23 | 12/23 | | |
|
|
|
|
|
|
|
|
|
NCT06046248: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease |
|
|
| Recruiting | 2 | 25 | US | Belumosudil, Rituximab | Northside Hospital, Inc., Sanofi | Chronic Graft Versus Host Disease | 12/26 | 12/27 | | |
NCT05996627: Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease |
|
|
| Recruiting | 2 | 82 | US | Belumosudil, KD 025, KD-025, KD025, Rho-associated Coiled-coil Kinase 2 Inhibitor KD025, ROCK-II Inhibitor KD025, ROCK2 Inhibitor KD025, SLx 2119, SLx-2119, SLx2119, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Electronic Health Record Review, Placebo Administration | Fred Hutchinson Cancer Center, Sanofi | Chronic Graft Versus Host Disease | 05/27 | 12/27 | | |
NCT06105554: Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 36 | US | Belumosudil mesylate | M.D. Anderson Cancer Center, Sanofi US Services, Inc | Multiple Myeloma | 08/27 | 08/29 | | |
| Recruiting | 1/2 | 258 | Europe, US, RoW | Isatuximab, SAR650984, Sarclisa®, Dexamethasone, Pomalidomide, Pomalyst®, Belantamab mafodotin, BLENREP®, Pegenzileukin, SAR444245, SAR439459, Belumosudil, SAR445761,, Rezurock, Evorpacept, ALX148 | Sanofi | Plasma Cell Myeloma Refractory | 07/27 | 03/28 | | |
NCT05918627: A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects |
|
|
| Completed | 1 | 32 | US | Belumosudil mesylate, SLx-2119, KD025, SAR445761, Placebo | Kadmon, a Sanofi Company | Immune System Disorder (Healthy Volunteer) | 12/09 | 12/09 | | |
NCT05918588: A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects |
|
|
| Completed | 1 | 32 | US | Belumosudil mesylate, KD025, SAR445761, Placebo | Kadmon, a Sanofi Company | Immune System Disorder (Healthy Volunteer) | 03/14 | 03/14 | | |
NCT05918614: A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects |
|
|
| Completed | 1 | 8 | US | Belumosudil mesylate, KD025, SAR445761, Placebo | Kadmon, a Sanofi Company | Immune System Disorder (Healthy Volunteer) | 06/14 | 06/14 | | |
NCT05806567: A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects |
|
|
| Completed | 1 | 52 | US | Belumosudil, REZUROCK/KD025/SAR445761, UGT1A1 victim drug, P-gp victim drug, OATP1B1/BCRP victim drug | Kadmon, a Sanofi Company | Immune System Disorder (Healthy Volunteers) | 10/22 | 10/22 | | |
NCT05806749: Immunological Tolerance in Patients With Mismatched Kidney Transplants |
|
|
| Active, not recruiting | 1 | 16 | US | Donor CD34+, CD3+. and belumosudil | University of California, Los Angeles | End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases | 08/25 | 08/26 | | |
| OPL-0401 / Valo Health |
Spectra, NCT05393284: Phase 2 Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy |
|
|
| Active, not recruiting | 2 | 114 | US | OPL-0401 Dose 1, Placebo | Valo Health, Inc. | Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy | 08/24 | 08/24 | | |
| rovadicitinib (TQ05105) / Sino Biopharm |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
| Recruiting | 2 | 105 | RoW | TQ05105 tablets, Hydroxycarbamide tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Moderate and High Risk Myelofibrosis | 03/23 | 09/23 | | |
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease |
|
|
| Recruiting | 2 | 40 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 10/25 | 04/26 | | |
NCT04944043: A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease |
|
|
| Active, not recruiting | 1/2 | 45 | RoW | TQ05105 Tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 06/23 | 12/24 | | |
NCT04941404: A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) |
|
|
| Active, not recruiting | 1/2 | 13 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Glucocorticoid-Refractory aGVHD | 07/23 | 12/24 | | |
NCT06245941: A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) |
|
|
| Recruiting | 1/2 | 93 | RoW | TQ05105 tablets, TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 06/26 | 05/27 | | |
NCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) |
|
|
| Recruiting | 1/2 | 92 | RoW | TQ05105 Tablets, TQB3617 Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 12/26 | 04/27 | | |
NCT05982106: To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects |
|
|
| Completed | 1 | 16 | RoW | TQ05105 Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 07/21 | 07/21 | | |
NCT04326348: A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH） |
|
|
| Recruiting | 1 | 40 | RoW | TQ05105 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hemophagocytic Lymphohistiocytosis | 01/22 | 07/22 | | |
NCT06388759: TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients |
|
|
| Active, not recruiting | 1 | 9 | RoW | TQ05105 Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 12/24 | 12/24 | | |
NCT06024915: A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets |
|
|
| Not yet recruiting | 1 | 40 | RoW | TQ05105 tablets, Itraconazole capsule, Rifampicin Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 10/23 | 12/23 | | |
NCT06598956: To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects |
|
|
| Not yet recruiting | 1 | 32 | RoW | TQ05105 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 07/25 | 08/25 | | |
| zelasudil (RXC007) / Redx |
2022-000498-15: A study to investigate the safety, tolerability, and potential effect of RXC007 in patients with IPF. Uno studio per studiare la sicurezza, la tollerabilità e il potenziale effetto di RXC007 nei pazienti con IPF. |
|
|
| Not yet recruiting | 2 | 64 | Europe, RoW | RXC007 20 mg Capsule, RXC007 50 mg Capsule, [NA], Capsule, hard | Redx Pharma plc, Redx Pharma Plc, Redx Pharma Plc, Redx Pharma PLC | Idiopathic Pulmonary Fibrosis (IPF) Fibrosi polmonare idiopatica (IPF), Lung condition associated with fibrosis and inflammation Condizione polmonare associata a fibrosi e infiammazione, Body processes [G] - Physiological processes [G07] | | | | |
| Active, not recruiting | 2 | 48 | Europe, RoW | RXC007, Placebo | Redx Pharma Plc, Simbec-Orion Group | IPF, Fibrosis | 06/24 | 01/25 | | |
|
NCT04931147: A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers |
|
|
| Completed | 1 | 90 | Europe | RXC007, RXC007 Matching Placebo | Redx Pharma Plc, Simbec Research | Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis, Non-alcoholic Steatohepatitis, Liver Diseases, Kidney Diseases | 03/23 | 03/23 | | |
| TDI01 / Graviton Biosci |
NCT06102083: A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis |
|
|
| Not yet recruiting | 2 | 120 | NA | TDI01 suspension | Beijing Tide Pharmaceutical Co., Ltd | Idiopathic Pulmonary Fibrosis | 08/25 | 03/26 | | |
NCT06169722: TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD)) |
|
|
| Recruiting | 1/2 | 120 | RoW | TDI01 suspension | Beijing Tide Pharmaceutical Co., Ltd | GVHD, Chronic | 02/25 | 08/27 | | |
ChiCTR2200058868: Safety, tolerability, and drug administration of the suspension in single/multiple doses in Chinese healthy subjects Phase I clinical study of TDI01 kinetic characteristics and food effects |
|
|
| Not yet recruiting | 1 | 62 | | Single dose study ;Food impact research ;multiple dose study | Chinese PLA General Hospital; Chinese PLA General Hospital, sponser | Idiopathic pulmonary fibrosis | | | | |
ChiCTR2300071134: A drug interaction study evaluating TDI01 suspension with omeprazole enteric-coated capsules in healthy subjects |
|
|
| Not yet recruiting | 1 | 24 | | D1 to D2: 40mg omeprazole enteric coated capsules orally on an empty stomach; 400mg TDI01 suspension orally on an empty stomach from D3 to D7; and 40mg omeprazole enteric coated capsules and 400mg TDI01 suspension orally on an empty stomach at D7 | Chinese PLA General Hospital; Chinese PLA General Hospital, TIDE pharmaceutical | Idiopathic pulmonary fibrosis | | | | |
ChiCTR2400082056: An exploratory clinical trial to evaluate the safety and efficacy of TDI01 suspension in the patients with hepatic fibrosis |
|
|
| Recruiting | N/A | 12 | | TDI01 200mg QD ; TDI01 400mg QD | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Self-raised | Hepatic fibrosis | | | | |
| VVN539 / VivaVision |
| No trials found |
| NRL-1049 / Neurelis |
| No trials found |
| QR056251 / Createrna |
| No trials found |
